Peer-Reviewed Publication
Drug Deliv2026;33(1):2660007.December 31, 2026Journal Article
Angiopep-2-decorated bacterial outer membrane vesicles penetrate the blood-brain barrier for glioblastoma chemo-immunotherapy.
Pir Tariq Shah1,2,3, Zhangrong Lou3, Xiaojing Zhu2, Wenrui Jin2, Chen Chen2, Tao Hu2, Peng Guo2, Xuanzhu Zhao3, Fan Li2, Yin Xiaoliang4,5, Zhenyong Wu2,6, Chengjun Wu1
1Core Laboratory, Qingdao Central Hospital, School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, Shandong Province, China.
2Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong province, China.
3Faculty of Medicine, School of Basic Medical Sciences, Dalian University of Technology, Dalian, Liaoning Province, China.
4Department of Neurosurgery, Peking University Third Hospital, Beijing, China.
5Center for Precision Neurosurgery and Oncology, Peking University Health Science Center, Beijing, China.
6Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Abstract
Glioblastoma (GBM) therapy remains one of the most formidable challenges in oncology because of the blood-brain barrier (BBB), immunosuppressive tumor microenvironment, and drug resistance. To overcome these challenges, we designed engineered angiopep-2-decorated bacterial outer membrane vesicles for targeted drug delivery across the BBB. Using a novel autotransporter-based (AIDA-I) genetic engine…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans